ASMQ available in Brazil, India, Malaysia, Myanmar, Tanzania, Vietnam, Niger, Burkina Faso, Thailand, Cameroon and Cambodia!
900,000 treatments distributed Included in the Essential Medicines List (EML) and Essential Medicines List for children (EMLc) of the WHO in 2013
|
![]() Click on the map to enlarge |
![]() April 2009 marked an important milestone for ASMQ as the first public order of treatments was completed by Brazilian government.
An active Pharmacovigilance plan is being put in place in Brazil. Admission of Farmanguinhos/Fiocruz to the PAHO Strategic Fund in April 2013 will allow procurement by South American national control programs. |
||
![]() In December 2011, ASMQ was registered in India. In 2012, it was registered in Malaysia (March) and Myanmar (September). In Vietnam, in December 2013, low strength ASMQ was registered. High strength was registered in April 2014. A comparison of ACTs has been performed in Myanmar between December 2008 and March 2009. This important study showed very favorable results for the FDC. [see results published in The Lancet Infectious Diseases] A WHO study on 45 patients was completed in Cambodia, showing overall favorable results. [see results published in Malaria Journal] A phase III trial is ongoing in Thailand on 1000 pregnant women comparing the efficacy, safety and pharmacokinetics of ASMQ FDC, DHA-PQ and artmether-lumefantrine. In March 2015, ASMQ was registered in Thailand and Cambodia. Registration is pending in Laos, Philippines, Papua New Guinea, and Indonesia. |
||
![]() In December 2013, ASMQ was registered in Tanzania. In 2014, it was registered in Niger (June) and Burkina Faso (September). In March 2016, ASMQ was registered in Cameroon. Registration is pending in Kenya, Ghana, Benin, Togo, Chad, Ivory Coast, Republic of Guinea, Senegal, Democratic Republic of Congo, Malawi, Congo, and Mali. |
||